Ximelagatran: AstraZeneca

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 246-251

  Hopfner, Rob ^a  

^a Chestnut Run Plaza WR 1051   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; H 376; H 388 57; H 415 04; MELAGATRAN; PRODRUG; RECOMBINANT HIRUDIN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE DISEASE; AGE; AREA UNDER THE CURVE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; NONHUMAN; PHARMACODYNAMICS; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VEIN THROMBOSIS;

AZETIDINES; BENZYLAMINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0036230309     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Drug development pipeline
2. Astra Merck joint venture is not impediment to growth for Astra, firm tells analysts; Joint venture has rights to epilepsy, thrombolytic projects in the US
3. United Kingdom Pharmaceuticals: Zeneca
4. Pan-Europe Pharmaceuticals: Pan-European Pharmaceutical Review
5. AstraZeneca progresses key products and aims to double product portfolio value every five years
6. Single and repeated oral dosing of H376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects
7. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use
8. AstraZeneca Plc's First Pharmaceuticals R&D Presentation, London, UK
9. American Society of Hematology 41st Annual Meeting (Part VI), New Orleans, LA, USA
10. AstraZeneca emphasizes size as key to growth in Rx market
11. First large-scale clinical study evaluates AstraZeneca's investigational anticoagulant - European multi-enter trial compares H-376/95 regimen with Dalteparin in the prevention of venous thromboembolism in orthopedic surgery
12. AstraZeneca - Nexium: A product or dose effect?
13. To enter top 10 in Japanese market by 2005: Dr McKillop of AstraZeneca
14. Pharmaceutical Models: Europe
15. Antithrombotic effects of H 376/95, an oral direct thrombin inhibitor, in an ex vivo human model of arterial thrombosis
16. Effect of melagatran, the active form of the oral direct thrombin inhibitor, H 376/95, on platelet deposition and relative thrombus size in porcine, coronary artery over-stretch injury model
17. Antithrombotic effects of H 376/95, an oral direct thrombin inhibitor, in an ex vivo human model of arterial thrombosis
18. The oral, direct thrombin inhibitor H 376/95 reduced thrombin size in deep venous thrombus treatment conscious rat model
19. Lehman Brothers: Pharmaceuticals United Kingdom: AstraZeneca
20. AstraZeneca anticoagulant NDA delayed; Crestor v Lipitor data in March
21. UK - Pharmaceuticals: AstraZeneca
22. Global Healthcare Bulletin
23. AstraZeneca - Annual Report & Form 20-F 2000
24. American Society of Clinical Pharmacology and Therapeutics 2001 Annual Meeting, Poster Sessions Orlando, FL, USA
25. American Society for Clinical Pharmacology and Therapeutics 2001 Annual Meeting (Part II), Orlando, FL, USA
26. Pharmacokinetics (PK) of melagratran (M) after oral dosing with H 376/95 in healthy male subjects of different ethnic origin
27. Pharmacokinetics (PK) of melagatran (M) in young and elderly healthy subjects in orthopedic surgery patients
28. Effect of acetylsalicylic acid (ASA) on the pharmacodynamics (PD) and pharmacokinetics (PK) of melagatran (M), active form of the oral direct thrombin inhibitor H 376/95
29. Pharmacokinetics of H 376/95 (H): A novel oral direct thrombin inhibitor in patients undergoing total knee arthoplasty (TKA)
30. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects
31. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
32. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
33. Inhibition of thrombin generation by H 376/95, an oral, direct thrombin inhibitor, in shed blood from healthy male subjects
34. Effects of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95, on prothrombin time determined with 15 reagents of different sensitivities
35. Dose-ranging study of H 376/95, a novel, oral, direct thrombin inhibitor, and its subcutaneous formulation, melagatran, for prophylaxis of venous thromboembolism after total hip and total knee replacement; METHRO I
36. Dose-response study of the novel, oral, direct thrombin inhibitor, H376/95 and its active form, melagatran, given subcutaneously, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement: METHRO II
37. Effect of H 376/95, an oral, direct thrombin inhibitor, versus r-hirudin and enoxaparin on markers of thrombin generation and platelet activation in shed blood from healthy male subjects
38. Effects of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects
39. The pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), in orthopaedic surgery patients to prevent deep vein thrombosis and pulmonary embolism
40. World Congress of Neurology 17th Meeting (Part III), London, UK
41. International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part III) - Overnight report, Paris, France
42. International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part II) - Overnight report, Paris, France
43. AstraZeneca's novel oral anticoagulant studied as alternative to warfarin
44. A comparison of the pharmacokinetic of ximelagatran (pINN, formerly H 376/95) in young and healthy subjects
45. The impact of ethnic origin on the pharmacokinetics of orally administered ximelagatran (pINN, formerly H 376/95)
46. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of nipedipine, in healthy male volunteers
47. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of Diazepam, in healthy male volunteers
48. The effect of oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers
49. International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part VIII), Paris, France
50. International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part IX), Paris, France
51. R&D pipeline table
52. Melagatran. Astra
53. Pharmacokinetics (PK) of melagatran in young and elderly healthy subjects and orthopedic surgery patients
54. AstraZeneca: The pipeline's coming
55. Lack of effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran
56. The pharmacokinetics and pharmacodynamics of ximelagatran in patients with mild-to-moderate impairment of liver function
57. AstraZeneca R&D pipeline